These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37305431)

  • 1. Clinical Characteristics Associated with Adherence and Persistence in Patients with Type 2 Diabetes Mellitus Treated with Dulaglutide.
    Lee DSU; Lee H
    J Diabetes Res; 2023; 2023():7917641. PubMed ID: 37305431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.
    Alatorre C; Fernández Landó L; Yu M; Brown K; Montejano L; Juneau P; Mody R; Swindle R
    Diabetes Obes Metab; 2017 Jul; 19(7):953-961. PubMed ID: 28181725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.
    Mody R; Huang Q; Yu M; Zhao R; Patel H; Grabner M; Landó LF
    Diabetes Obes Metab; 2019 Apr; 21(4):920-929. PubMed ID: 30520248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice.
    Mody R; Manjelievskaia J; Marchlewicz EH; Malik RE; Zimmerman NM; Irwin DE; Yu M
    Clin Ther; 2022 Apr; 44(4):537-554. PubMed ID: 35264311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment.
    Mody R; Grabner M; Yu M; Turner R; Kwan AYM; York W; Fernández Landó L
    Curr Med Res Opin; 2018 Jun; 34(6):995-1003. PubMed ID: 29271258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data.
    Mody R; Yu M; Nepal B; Konig M; Grabner M
    Diabetes Obes Metab; 2021 Jan; 23(1):106-115. PubMed ID: 32945083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
    Gor D; Lee TA; Schumock GT; Walton SM; Gerber BS; Nutescu EA; Touchette DR
    J Manag Care Spec Pharm; 2020 Jan; 26(1):67-75. PubMed ID: 31880221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.
    Uzoigwe C; Liang Y; Whitmire S; Paprocki Y
    Diabetes Ther; 2021 May; 12(5):1475-1489. PubMed ID: 33837922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN).
    Guo L; Li L; Yu Q; Wang N; Chen J; Wang Z; Ding Y
    Diabetes Ther; 2022 Jun; 13(6):1231-1244. PubMed ID: 35583797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
    García-Pérez LE; Boye KS; Rosilio M; Jung H; Heitmann E; Norrbacka K; Federici MO; Gentilella R; Guerci B; Giorgino F; Aigner U; Sapin H
    Diabetes Ther; 2021 Jul; 12(7):1929-1946. PubMed ID: 34097244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study.
    Kim HS; Cho YK; Kim MJ; Jung CH; Park JY; Lee WJ
    Front Endocrinol (Lausanne); 2022; 13():1032793. PubMed ID: 36387922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results.
    Mody R; Yu M; Grabner M; Boye K; Teng CC; Kwan AYM
    Clin Ther; 2020 Nov; 42(11):2184-2195. PubMed ID: 33256915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
    Guerci B; Giorgino F; Sapin H; Boye K; Lebrec J; Federici MO; Heitmann E; Dib A; Füchtenbusch M; García-Pérez LE
    Diabetes Obes Metab; 2022 Dec; 24(12):2373-2382. PubMed ID: 35876235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review.
    Robinson S; Boye KS; Mody R; Strizek AA; Konig M; Malik RE; Kennedy-Martin T
    Diabetes Ther; 2020 Jul; 11(7):1437-1466. PubMed ID: 32524494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States.
    Hoog M; Smith JL; Yu M; Peleshok J; Mody R; Grabner M
    Clin Ther; 2022 Jun; 44(6):873-887. PubMed ID: 35618571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients.
    Morieri ML; Frison V; Rigato M; D'Ambrosio M; Tadiotto F; Paccagnella A; Simioni N; Lapolla A; Avogaro A; Fadini GP
    J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32301492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting.
    Boye KS; Mody R; Wu J; Lage MJ; Botros FT; Woodward B
    Clin Ther; 2018 Aug; 40(8):1396-1407. PubMed ID: 30093131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study.
    Mody R; Huang Q; Yu M; Patel H; Zhang X; Wang L; Grabner M
    BMJ Open Diabetes Res Care; 2019; 7(1):e000884. PubMed ID: 31875137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial.
    Wang W; Nevárez L; Filippova E; Song KH; Tao B; Gu L; Wang F; Li P; Yang J
    Diabetes Obes Metab; 2019 Feb; 21(2):234-243. PubMed ID: 30129089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.